Cargando…
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
The amino-acid composition of the immunoglobulin variable region has been observed to impact antibody pharmacokinetics (PK). Here, we sought to improve the PK of the broad HIV−1-neutralizing VRC01-class antibodies, VRC07-523LS and N6LS, by reducing the net positive charge in their variable domains....
Autores principales: | Kwon, Young D., Pegu, Amarendra, Yang, Eun Sung, Zhang, Baoshan, Bender, Michael F., Asokan, Mangaiarkarasi, Liu, Qingbo, McKee, Krisha, Lin, Bob C., Liu, Tracy, Louder, Mark K., Rawi, Reda, Reveiz, Mateo, Schaub, Andrew J., Shen, Chen-Hsiang, Doria-Rose, Nicole A., Lusso, Paolo, Mascola, John R., Kwong, Peter D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288911/ https://www.ncbi.nlm.nih.gov/pubmed/37345226 http://dx.doi.org/10.1080/19420862.2023.2223350 |
Ejemplares similares
-
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
por: Kwon, Young D., et al.
Publicado: (2021) -
Improvement of antibody functionality by structure-guided paratope engraftment
por: Liu, Qingbo, et al.
Publicado: (2019) -
Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018) -
Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies
por: Chuang, Gwo-Yu, et al.
Publicado: (2020) -
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
por: Zhang, Baoshan, et al.
Publicado: (2023)